ABSTRACT: 27
Breast cancer is a complex disease and studying DNA methylation (DNAm) in tumors is 28 complicated by disease heterogeneity. We compared DNAm in breast tumors with 29 normal-adjacent breast samples from The Cancer Genome Atlas (TCGA). We 30 constructed models stratified by tumor stage and PAM50 molecular subtype and 31 performed cell-type reference-free deconvolution on each model. We identified nineteen 32 differentially methylated gene regions (DMGRs) in early stage tumors across eleven 33 genes (AGRN, C1orf170, FAM41C, FLJ39609, HES4, ISG15, KLHL17, NOC2L, 34 PLEKHN1, SAMD11, WASH5P). These regions were consistently differentially 35 methylated in every subtype and all implicated genes are localized on chromosome 36 1p36.3. We also validated seventeen DMGRs in an independent data set. Identification 37 and validation of shared DNAm alterations across tumor subtypes in early stage tumors 38 advances our understanding of common biology underlying breast carcinogenesis and 39 may contribute to biomarker development. We also provide evidence on the importance 40 and potential function of 1p36 in cancer. 41
INTRODUCTION: 42
Invasive breast cancer is a complex disease characterized by diverse etiologic 43 factors 1 . Key genetic and epigenetic alterations are recognized to drive tumorigenesis and 44 serve as gate-keeping events for disease progression 2 . Early DNA methylation (DNAm) 45 events have been shown to contribute to breast cancer development 3 . Importantly, DNAm 46 alterations have been implicated in the transition from normal tissue to neoplasia 4,5 and 47 from neoplasia to metastasis 6 . Furthermore, patterns of DNAm are known to differ across 48 molecular subtypes of breast cancer 7 -Luminal A (LumA), Luminal B (LumB), Her2-49 enriched and Basal-likeidentified based on the prediction analysis of microarray 50 (PAM50) 50 classification 8 . However, while DNAm differences across breast cancer subtypes have 51 been explored, similarities across subtypes are less clear 9 . Such similarities found in early 52 stage tumors can inform shared biology underpinning breast carcinogenesis andas 53 similarities would be agnostic to subtypepotentially contribute to biomarkers for early 54 detection. 55
Studying DNAm in bulk tumors is complicated by disease heterogeneity. 56
Heterogeneity is driven by many aspects of cancer biology including variable cell-type 57
proportions found in the substrate used for molecular profiling 10 . Different proportions of 58 stromal, tumor, and infiltrating immune cells may confound molecular profile 59 classification when comparing samples 11 because cell types have distinct DNAm 60 patterns 12-14 . The potential for cell-type confounding prompted the development of 61 statistical methods to adjust for variation in cell-type proportions in blood 15 and solid 62 tissue 16 . One such method, RefFreeEWAS, is a reference-free deconvolution method and 63 does not require a reference population of cells with known methylation patterns and is 64 agnostic to genomic location when performing deconvolution 17 . Instead, the unsupervised 65 method infers underlying cell-specific methylation profiles through constrained non-66 negative matrix factorization (NMF) to separate cell-specific methylation differences 67 from actual aberrant methylation profiles observed in disease states. This method has 68 previously been shown to effectively determine the cell of origin in breast tumor 69 phenotypes 18 . 70
We applied RefFreeEWAS to The Cancer Genome Atlas (TCGA) breast cancer 71
DNAm data and estimated cell proportions across the set. We compared tumor DNAm 72 with adjacent normal tissue stratified by tumor subtype 9 and identified common early 73 methylation alterations across molecular subtypes that are independent of cell type 74 composition. We identified a specific chromosomal location, 1p36.3, that harbors all 19 75 of the differentially methylated regions that are in common to early stage breast cancer 76 subtypes. 1p36 is a well-studied and important region in many different cancer types, but 77 there remain questions about how it may impact carcinogenesis and disease 78 progression 19 . Our study provides evidence that methylation in this region may provide 79 important clues about early events in breast cancer. We also performed RefFreeEWAS on 80 an independent validation set (GSE61805) and confirmed these results 20 . 81
82

RESULTS: 83
DNA methylation deconvolution 84
Subject age and tumor characteristic data stratified by PAM50 subtype and stage 85 is provided in Table 1 for the 523 TCGA tumors analyzed. TCGA breast tumor sample 86 purity, estimated by pathologists from histological slides, was consistent across PAM50 87 subtypes and stages indicating that observed methylation differences are not 88 predominantly a result of large differences in tumor purity ( Supplementary Fig. S1 ). To 89 correct for cell-proportion differences across tumor samples, we estimated the number of 90 cellular methylation profiles contributing to the mixture differences by applying NMF to 91 the matrix of beta values, which resulted in model specific dimensionality estimates 92 indicating diverse cellular methylation profiles ( Supplementary Table S1 ). The reference-93 free deconvolution altered the number and extent of significant differentially methylated 94
CpGs across all models that compared breast tumor methylation with adjacent normal 95 samples ( Supplementary Fig. S2 ). 96 In early stage tumors, we identified a set of nineteen DMGRs shared among 99
Luminal A, Luminal B, Her2, and Basal-like subtypes (DMGRs Q < 0.01, Figure 1A ). In Subtype specific methylation patterns in early stage tumors were most divergent for 108
Basal-like tumors versus other types, while in late stage tumors methylation alterations in 109
Luminal B tumors were most divergent ( Supplementary Table S2 ). To test if collapsing 110 by genomic region had an appreciable effect on detecting DMGRs, we compared DMGR 111 results to results derived from regions defined by CpG island status (i.e. CpG island, 112
Shore, Shelf, Open Sea). Using CpG island context designations indicated similar results 113 ( Supplementary Fig S3) , though a lower number of common DMGRs were observed. 114 Therefore, downstream analyses used DMGRs identified based on probe position in 115 relation to TSS. 116
We identified nineteen DMGRs with common methylation alterations among 117 tumor subtypes in comparison with normal tissues that were annotated to eleven genes: 118 AGRN, C1orf170, FAM41C, FLJ39609, HES4, ISG15, KLHL17, NOC2L, PLEKNH1, 119 SAMD11, and WASH5P ( Supplementary Table S3 ). 120
Dependent upon tumor subtype, some gene regions had a different directional 121 change in tumor methylation compared to normal tissue (e.g. C1orf170, HES4, and 122 ISG15). Additionally, of the eleven genes identified, we observed differential methylation 123 in different regions including gene body, promoter (TSS1500, and TSS200), and 3'UTR 124 (Table 2 and Supplementary Table S3 ). All nineteen DMGRs also had differential 125 methylation in at least one late stage tumor subtype, and thirteen of the nineteen DMGRs 126 were significantly differentially methylated across all tumor subtypes in late stage tumors 127 (Table 2 and Supplementary Table S4) DMGRs compared to all other regions (Fisher's Exact Test OR = 4.15, 95% CI = 1.04 -150 23.83, P = 0.04). All differentially methylated CpG probe IDs are given in 151 Supplementary Table S5 . DAVID pathway analysis applied to the top 400 most 152 aberrantly methylated genes in common to the four PAM50 subtypes identified the GO 153 term for the regulation of hormone levels to be significantly enriched (GO:0010817, FDR 154 = 0.035, Supplementary Table S6 ). 155 156
Breast cancer copy number alterations in 1p36 157
Among these 523 tumors, the prevalence of 1p36.3 copy number alteration was 158 only 1.2% (n=6), all were amplifications that affected ten of the eleven genes most distal 159 to the chromosome end. Among the six tumors with 1p36.3 amplification three were 160
Basal-like, two were Her2-enriched, and one was Luminal A. Exclusive of tumors with 161 copy number alterations, there was one tumor (Her2-enriched), with a truncating 162 mutation in KLHL17, and one tumor with a missense mutation in PLEKHN1 (Basal-like). 
DMGRs impact gene expression 167
We identified CpG sites with significant correlation of methylation with gene 168 expression for five genes (AGRN, PLEKHN1, KLHL17, SAMD11, and FAM41C) , 169 associated with eight DMGRs ( Supplementary Table S7 and Supplementary Figures S6-170   9) . Of the nineteen DMGRs identified, eighteen of them replicated in either one or 206 both late stage and independent validation sets. The one DMGR that did not replicate was 207 the WASH5P body. This region is located more than 830,000 base pairs (bp) away from 208 the much tighter region spanned by the remaining eighteen DMGRs (~188,000 bp), 209 suggesting a loose association between WASH5P and the other ten genes. 210
There is also additional evidence implicating the potential importance of the 211 identified genes assigned to the differentially methylated regions. For example, in a study 212 of mutational profiles in metastatic breast cancers, AGRN was more frequently mutated in 213 metastatic cancers compared with early breast cancers 33 . Similarly, expression of the 214 HES4 Notch gene is known to be significantly correlated with the presence of activating 215 mutations in multiple breast cancer cell lines, and is associated with poor patient 216 outcomes 34 . In addition, ISG15 has been implicated as a key player in breast 217 carcinogenesis 35 , though there is conflicting evidence 36 . However, the conflicting 218 evidence to date may be related to our observation of ISG15 hypomethylation in Basal-219
Like, Her2, and LumB tumors, and hypermethylation in LumA tumors (Supplementary 220 Table S3 ). Opposing methylation states among tumor subtypes relative to normal tissue 221 may contribute to subtype-specific roles of ISG15 dysregulation in breast carcinogenesis. 222
Additionally, the NOC2L gene has been identified as a member of a group of prognostic 223 genes derived from an integrated microarray of breast cancer studies 37 . We also identified 224 three DMGRs -TSS1500, Body, & 5'UTRin the SAMD11 gene, which has 225 significantly reduced expression in breast cancer cells compared to normal tissues 38 , 226 consistent with our findings of SAMD11 hypermethylation across all four breast cancer 227 subtypes. As DNAm changes were observed consistently and robustly across subtypes, it 228 is likely that several of the other identified genes are cancer initiation factors that require 229 additional study. 230 Importantly, we validated the identified DMGRs in an independent set of invasive 231 breast tumors and normal tissues. Our validation is strengthened by the lack of molecular 232 subtype assignments in the validation set. The validation of DMGRs in a setting agnostic 233 to intrinsic subtype indicates that differential magnitude or direction of methylation 234 alterations that may be present in different subtypes did not limit our ability to identify 235 We identified and validated DMGRs in early stage breast tumors across PAM50 249 subtypes that are located on chromosome 1p36.3. The observed differential methylation 250 suggests that this region may contribute to the initiation or progression to invasive breast 251 cancer. Additional work is needed to investigate the scope of necessary and sufficient 252 alterations to 1p36.3 for transformation and to more clearly understand the implications 253 of 1p36.3 methylation alterations to gene regulation. Further investigation of DNAm 254 changes to 1p36.3 may identify opportunities for early identification of breast cancer or 255 risk assessment. Lastly, the reference-free approach we used could be applied to 256 methylation datasets from other tumor types to identify potential drivers of 257 carcinogenesis common across histologic or intrinsic molecular subtypes. 258
PATIENTS & METHODS: 260
Data Processing 261
We accessed breast invasive carcinoma Level 1 Illumina HumanMethylation450 262 (450K) DNAm data (n = 870) from the TCGA data access portal and downloaded all 263 sample intensity data (IDAT) files. We processed the IDAT files with the R package 264 minfi using the "Funnorm" normalization method on the full dataset 39 . We filtered CpGs 265 with a detection P-value > 1.0E-05 in more than 25% of samples, CpGs with high 266 frequency SNP(s) in the probe, probes previously described to be potentially cross-267 hybridizing, and sex-specific probes 40,41 . We filtered samples that did not have full 268 covariate data (PAM50 subtype, pathologic stage 42,12 ) and full demographic data (age and 269 sex). All tumor adjacent normal samples were included regardless of missing data (n = 270 97, Table 1 ). 271 
Identifying differentially methylated gene regions 299
To understand the genomic regions with common DNAm alterations we grouped 300
CpGs by gene and region relative to genomic location (transcription start site 1500 301 (TSS1500), TSS200, 3' untranslated region (3'UTR), 5'UTR, 1 st exon, and gene body). 302
We used this gene-region taxonomy to collapse differentially methylated CpGs, as 303 defined by our Q-value cutoff, into specific differentially methylated gene regions 304 (DMGRs). This extended the Illumina 450K CpG annotation file to allow for a given 305
CpG to be associated with up to two genes depending on the proximity of the CpG site to 306 neighboring genes (Figure 3) . We defined a differentially methylated CpG as one with a Q-value < 0.01 following cell-313 type adjustment in a specific subtype model compared to normal tissue. To identify 314 DMGR sets for each stage and subtype, we analyzed all eight models independently. 315
316
Pathway Analysis 317
We performed a DAVID (the database for annotation, visualization and integrated 318 discovery) analysis 45,46 for the 400 genes with the lowest median CpG Q-values that are 319 in common to all early stage tumors regardless of PAM50 subtype, and extracted 320 enriched Gene Ontology (GO) 47 and Kyoto Encyclopedia of Genes and Genomes 321 (KEGG) 48 terms. We selected the top 400 genes based on recommended gene list sizes 49 . 322 323
Copy number, gene expression, and genomic location 324
We downloaded TCGA Breast Invasive Carcinoma CNV data 9 and normalized 325 RNAseq using cBioPortal 50 . For the DMGRs we identified, we analyzed the prevalence 326 of copy number alterations and mutations in each gene across all samples, stratified by 327 molecular subtype. Similarly, to determine whether these DMGRs affect gene expression 328 of their target gene, we calculated Spearman correlations of DNAm beta values in 329 significant CpGs (Q < 0.01) to matched sample Illumina HiSeq gene expression data. We 330 used a Bonferroni correction to determine significant expression differences, resulting in 331 an acceptance alpha value of 9.36E-5. 332
333
Validation 334
To confirm the identified early stage DMGRs in common among intrinsic 335 molecular subtypes we applied the analysis workflow to TCGA late stage tumors and an 336 independent validation set (GSE60185) 20 . The validation set includes samples of ductal 337 carcinoma in situ (DCIS), mixed, invasive, and normal histology collected from Akershus 338 University Hospital and from the Norwegian Radium Hospital. We analyzed only the 339 invasive samples compared to normal samples using the same bioinformatics pipeline of 340 quality control CpG filtering steps and normalization procedures. However, we did not 341 have complete age information or intrinsic subtype assignments for the validation set and 342 the models are not adjusted for age or stratified by subtype. This resulted in a single 
